John F. Sheridan Sells 9,538 Shares of Tandem Diabetes Care Inc (NASDAQ:TNDM) Stock

Tandem Diabetes Care Inc (NASDAQ:TNDM) CEO John F. Sheridan sold 9,538 shares of the stock in a transaction on Friday, September 6th. The stock was sold at an average price of $70.03, for a total value of $667,946.14. Following the transaction, the chief executive officer now owns 12,039 shares in the company, valued at approximately $843,091.17. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

TNDM traded down $6.43 on Monday, hitting $62.14. 120,304 shares of the stock were exchanged, compared to its average volume of 1,250,314. Tandem Diabetes Care Inc has a 12 month low of $26.40 and a 12 month high of $74.81. The business has a 50-day moving average of $64.90 and a two-hundred day moving average of $64.41. The company has a debt-to-equity ratio of 0.11, a current ratio of 2.53 and a quick ratio of 2.21. The firm has a market capitalization of $4.10 billion, a price-to-earnings ratio of -24.37 and a beta of 0.25.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, August 1st. The medical device company reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.20. Tandem Diabetes Care had a negative net margin of 19.55% and a negative return on equity of 19.31%. The firm had revenue of $93.26 million for the quarter, compared to analyst estimates of $69.95 million. During the same period last year, the firm earned ($0.33) EPS. The business’s quarterly revenue was up 173.2% compared to the same quarter last year. Equities research analysts expect that Tandem Diabetes Care Inc will post -0.65 earnings per share for the current fiscal year.

TNDM has been the subject of a number of research reports. Oppenheimer lifted their target price on Tandem Diabetes Care from $80.00 to $84.00 in a report on Friday, August 2nd. Lake Street Capital reaffirmed a “buy” rating on shares of Tandem Diabetes Care in a research report on Monday, June 17th. Bank of America reaffirmed a “neutral” rating and set a $65.00 price target on shares of Tandem Diabetes Care in a research report on Friday, May 17th. Svb Leerink initiated coverage on shares of Tandem Diabetes Care in a report on Monday, May 13th. They issued an “outperform” rating and a $83.00 price objective for the company. Finally, ValuEngine upgraded shares of Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a research report on Monday, August 12th. Four research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $70.71.

Institutional investors have recently modified their holdings of the company. Nisa Investment Advisors LLC increased its stake in Tandem Diabetes Care by 53.3% in the second quarter. Nisa Investment Advisors LLC now owns 460 shares of the medical device company’s stock valued at $30,000 after acquiring an additional 160 shares during the last quarter. Bremer Bank National Association acquired a new position in Tandem Diabetes Care during the first quarter valued at approximately $31,000. TRUE Private Wealth Advisors bought a new stake in Tandem Diabetes Care during the second quarter worth $33,000. James Investment Research Inc. lifted its stake in Tandem Diabetes Care by 15.9% during the second quarter. James Investment Research Inc. now owns 1,315 shares of the medical device company’s stock worth $85,000 after purchasing an additional 180 shares during the last quarter. Finally, Stephens Inc. AR acquired a new stake in shares of Tandem Diabetes Care in the 2nd quarter valued at $113,000. 79.50% of the stock is owned by institutional investors.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Further Reading: What is an Initial Coin Offering (ICO)?

Insider Buying and Selling by Quarter for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with's FREE daily email newsletter.